Detection of Loss of Heterozygosity in cfDNA of Advanced EGFR- or KRAS-Mutated Non-Small-Cell Lung Cancer Patients

Liquid biopsy is currently approved for management of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) patients. However, one unanswered question is whether the rate of cell-free DNA (cfDNA)-negative samples is due to technical limitations rather than to tumor genet...

Descripción completa

Detalles Bibliográficos
Autores principales: Boldrin, Elisa, Nardo, Giorgia, Zulato, Elisabetta, Bonanno, Laura, Polo, Valentina, Frega, Stefano, Pavan, Alberto, Indraccolo, Stefano, Saggioro, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981934/
https://www.ncbi.nlm.nih.gov/pubmed/31861832
http://dx.doi.org/10.3390/ijms21010066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981934/
https://www.ncbi.nlm.nih.gov/pubmed/31861832
http://dx.doi.org/10.3390/ijms21010066

Ejemplares similares